Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.46 USD | -4.58% | -9.32% | +65.91% |
05-15 | Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial | MT |
05-15 | Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+65.91% | 192M | |
+64.92% | 62.59B | |
-1.85% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.96% | 19.09B | |
+4.21% | 13.08B | |
+25.74% | 12.26B | |
+27.42% | 12.05B |
- Stock Market
- Equities
- ATOS Stock
- News Atossa Therapeutics, Inc.
- Atossa Therapeutics Files $100 Million Mixed-Shelf Offering